

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 August 2006 (17.08.2006)

PCT

(10) International Publication Number
WO 2006/084909 A1

(51) International Patent Classification:

A61L 27/54 (2006.01) A61L 29/08 (2006.01)
A61L 29/16 (2006.01) A61L 31/10 (2006.01)
A61L 31/16 (2006.01) A61K 31/00 (2006.01)
A61L 27/34 (2006.01)

(21) International Application Number:

PCT/EP2006/050888

(22) International Filing Date:

13 February 2006 (13.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

05002937.0 11 February 2005 (11.02.2005) EP
60/652,758 14 February 2005 (14.02.2005) US

(71) Applicant (for all designated States except US): **NOLabs AB** [SE/SE]; Kungsgatan 6, S-252 21 Helsingborg (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PETERS, Tor** [SE/CH]; Chalet Marabou Bodemos, CH-1659 Rougemont (CH).

(74) Agent: **KRAHBICHLER, Erik**; Ström & Gulliksson AB, Järnvägsgatan 3, S-252 24 Helsingborg (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DEVICE FOR TREATMENT OF DISORDERS IN THE ORAL CAVITY WITH NITRIC OXIDE, AND MANUFACTURING PROCESS FOR THE SAME

10



(57) Abstract: A device and method for therapeutical treatment of disorders in the oral cavity and a process for manufacturing of said device is disclosed. The device comprises a nitric oxide (NO) eluting polymer. The nitric oxide (NO) eluting polymer is configured to elute a therapeutic dosage of nitric oxide (NO) when used in the oral cavity. The device allows for target treatment of infections or wounds in the oral cavity. The device comprising the nitric oxide (NO) eluting polymer is arranged to contact an infected area in the oral cavity, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO).

DEVICE FOR TREATMENT OF DISORDERS IN THE ORAL CAVITY WITH NITRIC OXIDE, AND MANUFACTURING PROCESS FOR THE SAME**Field of the Invention**

5 This invention pertains in general to the field of
therapeutical treatment of disorders in the oral cavity.
More particularly the invention relates to a device and
method of treatment of disorders in the oral cavity and a
process for manufacturing of said device, involving Nitric
10 Oxide (NO).

Background of the Invention

 Infections by bacteria, viruses, fungi or yeasts are
the underlying cause of many complications during wound
15 care. A wide range of treatments has been developed to
control such disorders, including physical and chemical
methods and antimicrobial agents of a wide variety of
antimicrobial agents. Despite the widespread use of these
approaches, it is generally recognised that our ability to
20 halt the invasion, persistence and spread of microbial
infections remain limited.

 Treatment of disorders in the oral cavity, such as
paradontosis, is especially difficult, since the mucous
membrane in the oral cavity is exposed to a variety of
25 substances from the external (outside of the body)
environment. Up to now the only reliable treatment of
infections in the oral cavity appears to be the use of
antibiotics. Treatment with antibiotics has certain
disadvantages, such as that the bacteria develops tolerance
30 and resistance to the antibiotics over time, and thus
become difficult to eradicate.

 It is known that nitric oxide (NO) provides an
alternative to conventional therapies, such as antibiotics.
Nitric oxide is a highly reactive molecule that is involved
35 in many cell functions. In fact, nitric oxide plays a
crucial role in the immune system and is utilized as an
effector molecule by macrophages to protect itself against

a number of pathogens, such as fungi, viruses, bacteria etc., and general microbial invasion. This improvement of healing is partly caused by NO inhibiting the activation or aggregation of blood platelets, and also by NO causing a
5 reduction of inflammatory processes at the site of an implant. Furthermore, NO has a vasodilating effect, which effect also affect, and promote, the healing process.

NO is also known to have an anti-pathogenic, especially an anti-viral, effect, an anti-sacral effect,
10 and furthermore NO has an anti-cancerous effect, as it is cytotoxic and cytostatic in therapeutic concentrations, i.e. it has among other effects tumoricidal and bacteriocidal effects. NO has for instance cytotoxic effects on human haematological malignant cells from
15 patients with leukaemia or lymphoma, whereby NO may be used as a chemotherapeutic agent for treating such haematological disorders, even when the cells have become resistant to conventional anti-cancer drugs. This anti-pathogenic and anti-tumour effect of NO is taken advantage
20 of by the present invention, without having adverse effects as for instance many anti-cancer drugs.

However, due to the short half-life of NO, it has hitherto been very hard to treat viral, bacteria, virus, fungi or yeast infections with NO. This is because NO is
25 actually toxic and has negative effects when applied in too large amounts to the body. NO is actually also a vasodilator, and too large amounts of NO introduced into the body will cause a complete collapse of the circulatory system. On the other hand, NO has a very short half-life of
30 fractions of a second up to a few seconds, once it is released. Hence, administration limitations due to short half-life and toxicity of NO have been limiting factors in the use of NO in the field of anti-pathogenic and anti-cancerous treatment so far.

In recent years research has been directed to polymers with the capability of releasing nitrogen oxide when getting in contact with water. Such polymers are for example polyalkyleneimines, such as L-PEI (Linear
5 PolyEthyleneImine) and B-PEI (Branched PolyEthyleneImine), which polymers have the advantage of being biocompatible.

US 2004/265244 discloses a composition and a method directed to antimicrobial release of NO, in order to prevent gingival and other mucosal diseases. The elution of
10 NO from the device in US 2004/265244 is initiated by light activation of a nitosyl-containing organometallic compound. Hence, the activation process of US 2004/265244 is complicated. Furthermore, nothing is mentioned in US 2004/265244 about regulating the release on nitric oxide
15 from the device.

US 5,958,427 describes NO-donor compounds and pharmaceutical compositions containing such NO-donor compounds, for delivering NO to the apical surface of a mucosa. Nothing is mentioned in US 5,958,427 about
20 regulating the release on nitric oxide from the device.

EP 1 300 424 discloses extremely hydrophobic NO releasing polymers. These polymers are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. Since the polymer according to EP 1 300
25 424 is extremely hydrophobic, it is very unlikely that a sufficient elution on nitric oxide may be obtained in the oral cavity. The mentioning of polyethylenimine, page 9, line 35, is only in respect of excipient polymers to be included in blends and copolymers. Nothing is mentioned in
30 EP 1 300 424 about regulating the release on nitric oxide from the device.

US 5,691,423 discloses a polymeric, and pharmaceutical, composition capable of releasing NO, said polymeric composition comprising a polysaccharide including
35 a NO releasing N_2O_2^- functional group bound to the polymer.

Nothing is mentioned in US 5,691,423 about regulating the release on nitric oxide from the device.

US 6,737,447 discloses a coating for medical devices, which coating provides NO delivery by using nanofibers of L-PEI. US 6,737,447 points out, and stresses, that the coating is insoluble in water. This can only be interpreted as the release of NO is initiated by something else than water. Furthermore, nothing is mentioned in US 6,737,447 about regulating the release on nitric oxide from the device.

Other example for NO eluting polymers are given in US-5,770,645, wherein polymers derivatized with at least one -NO_x group per 1200 atomic mass unit of the polymer are disclosed, X being one or two. One example is an S-nitrosylated polymer and is prepared by reacting a polythiolated polymer with a nitrosylating agent under conditions suitable for nitrosylating free thiol groups.

Akron University has developed NO-eluting L-PEI molecule that can be nano-spun onto the surface of medical devices such as implanted grafts, showing significant improvement of the healing process and reduced inflammation when implanting such devices. According to US-6,737,447, a coating for medical devices provides nitric oxide delivery using nanofibers of linear poly(ethylenimine)-diazoniumdiolate. Linear poly(ethylenimine)diazoniumdiolate releases nitric oxide (NO) in a controlled manner to tissues and organs to aid the healing process and to prevent injury to tissues at risk of injury. Electrospun nano-fibers of linear poly(ethylenimine) diazoniumdiolate deliver therapeutic levels of NO to the tissues surrounding a medical device while minimizing the alteration of the properties of the device. A nanofiber coating, because of the small size and large surface area per unit mass of the nanofibers, provides a much larger surface area per unit

mass while minimizing changes in other properties of the device.

However, the disclosure is both silent concerning an improvement of present technology in respect of treatment
5 of disorders in the oral cavity, and the anti pathogenic potential of nitric oxide, and how such treatment could be regulated.

Hence, an improved, and more advantageous, device for the treatment and/or prevention of infection, caused by
10 bacteria, viruses, fungi or yeasts, herpes. It is desired that said device does not develop bacteria resistance, does increase circulation, acts as a healing promoter. It is further desired that the treatment could be regulated. It would be advantageous, in particular, to provide a device
15 allowing for target treatment of both osteosynthetic and soft tissue healing post dental implant. Prevention and treatment of paradontosis or other infected wounds and cancer, and increased circulation, in the oral cavity, by means of such a device, would be advantageous.

20

Summary of the Invention

Accordingly, the present invention preferably seeks to mitigate, alleviate or eliminate one or more of the above-identified deficiencies in the art and disadvantages
25 singly or in any combination and solves, among others, the problems mentioned above, by providing a device according to the appended patent claims.

According to one aspect of the invention, a device is provided that allows for target treatment of infections or
30 wounds in the oral cavity. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the infected area in the oral cavity, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area.

According to another aspect of the invention, a manufacturing process for such a device is provided, wherein the process is a process for forming a device that allows for target treatment of infections or wounds in the oral cavity. The process comprises selecting a plurality of nitric oxide eluting polymeric fibers, and deploying said nitric oxide eluting fibers in a patch or pad to be comprised in said device.

The present invention has at least the advantage over the prior art that it provides target exposure of an infected or wounded area to NO, whereby a very effective anti-viral, anti-bacterial, anti-fungi and/or anti-cancer therapy is achievable.

Brief Description of the Drawings

These and other aspects, features and advantages of which the invention is capable of will be apparent and elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which

Fig. 1 is a schematic illustration of a sponge according to the invention,

Fig. 2 is a schematic illustration of a patch or pad according to the invention,

Fig. 3 is a schematic illustration of another patch or pad according to the invention, with NO-elution in one direction only,

Fig. 4 is a schematic illustration of a condom/sheath according to the invention,

Fig. 5 is a schematic illustration of nano-particles, or micro-spheres, according to the invention,

Fig. 6 is a schematic illustration of a mouth wash according to the invention, and

Fig. 7 is an illustration of two elution profiles for two different mixtures of nitric oxide eluting polymer and carrier material.

5 **Description of Embodiments**

The following description focuses on an embodiment of the present invention applicable to a device, in form of a pad or patch, which allows for target treatment of infections or wounds in the oral cavity, such as
10 paradontosis, herpes etc. However, also alternative embodiments are described.

With regard to nitric oxide (nitrogen monoxide, NO), its physiological and pharmacological roles have attracted much attention and thus have been studied. NO is
15 synthesized from arginine as the substrate by nitric oxide synthase (NOS). NOS is classified into a constitutive enzyme, cNOS, which is present even in the normal state of a living body and an inducible enzyme, iNOS, which is produced in a large amount in response to a certain
20 stimulus. It is known that, as compared with the concentration of NO produced by cNOS, the concentration of NO produced by iNOS is 2 to 3 orders higher, and that iNOS produces an extremely large amount of NO.

In the case of the generation of a large amount of NO
25 as in the case of the production by iNOS, it is known that NO reacts with active oxygen to attack exogenous microorganisms and cancer cells, but also to cause inflammation and tissue injury. On the other hand, in the case of the generation of a small amount of NO as in the
30 case of the production by cNOS, it is considered that NO takes charge of various protective actions for a living body through cyclic GMP (cGMP), such as vasodilator action, improvement of the blood circulation, antiplatelet-
aggregating action, antibacterial action, anticancer
35 action, acceleration of the absorption at the digestive

tract, renal function regulation, neurotransmitting action, erection (reproduction), learning, appetite, and the like. Heretofore, inhibitors of the enzymatic activity of NOS have been examined for the purpose of preventing
5 inflammation and tissue injury, which are considered to be attributable to NO generated in a large amount in a living body. However, the promotion of the enzymatic activity (or expressed amount) of NOS (in particular, cNOS) has not been examined for the purpose of exhibiting various protective
10 actions for a living body by promoting the enzymatic activity of NOS and producing NO appropriately.

In recent years research has been directed to polymers with the capability of releasing nitrogen oxide when getting in contact with water. Such polymers are for
15 example polyalkyleneimines, such as L-PEI (Linear PolyEthyleneImine) and B-PEI (Branched PolyEthyleneImine), which polymers have the advantage of being biocompatible.

The polymers may be manufactured by electro spinning, gas spinning, air spinning, wet spinning, dry spinning,
20 melt spinning, and gel spinning. Electro spinning is a process by which a suspended polymer is charged. At a characteristic voltage a fine jet of polymer releases from the surface in response to the tensile forces generated by interaction by an applied electric field with the
25 electrical charge carried by the jet. This process produces a bundle of polymer fibres, such as nano-fibres. This jet of polymer fibres may be directed to a surface to be treated.

In other embodiments the polymers may be manufactured
30 by air spinning, wet spinning, dry spinning, melt spinning, or gel spinning.

Furthermore, US 6,382,526, US 6,520,425, and US 6,695,992 disclose alternative processes and apparatuses for the production of such polymeric fibres. These
35 techniques are generally based on gas stream spinning, also

known within the fiber forming industry as air spinning, of liquids and/or solutions capable of forming fibers.

In an embodiment of the invention, according to Fig. 1, the device 10 is in form of a nano-spun, NO-eluting sponge or fiber coated sponge or sponge-like device, such as a sponge or a cotton ball or pillow. This NO-eluting sponge may be placed between the lip and teeth to increase circulation and prevent infection. When the nano-spun, NO-eluting sponge according to the present invention gets in contact with the moisture in the oral cavity the NO-eluting sponge starts to release NO to the area to be treated. This nano-spun NO-eluting sponge is preferably comprised of nano-spun fibres of a polymer that elutes NO. Such polymers are for example polyalkyleneimines, such as L-PEI (Linear PolyEthyleneImine) or B-PEI (Branched PolyEthyleneImine), which polymers have the advantage of being biodegradable to natural products or biocompatible with the latter.

This sponge has the advantage that it is easily activated. Furthermore, the NO is applied locally, without influencing other parts of the body, due to the short half-life of the NO eluted from the NO eluting polymer material. Thus, implications concerning the vascular system are kept very local and low, while at the same time the effect of NO is optimally exploited.

In another embodiment the sponge according to an embodiment of the present invention is applied to the oral cavity with the aid of a stick or pin at the area to be treated. This area may be anywhere in the oral cavity, such as between the gum and the teeth, between the teeth, in a dental pocket, etc. More specifically, the sponge is for instance releasably attached to the stick, preferably to an end of the stick. The end is then introduced into the oral cavity together with the sponge, where it is released from the stick, e.g. by counter holding the sponge with two fingers and drawing back the stick. The stick is thus

removed from the oral cavity, leaving the sponge behind in the oral cavity for treatment therein.

Akron University has developed NO-eluting L-PEI molecule that can be nano-spun onto the surface of medical devices permanently implantable into the human body, showing significant improvement of the healing process and reduced inflammation when implanting such devices. According to US-6,737,447, a coating for medical devices provides nitric oxide delivery using nanofibers of linear poly(ethylenimine)-diazoniumdiolate. Linear poly(ethylenimine)diazoniumdiolate releases nitric oxide (NO) in a controlled manner.

However, the meaning of "controlled" in the context of US 6,737,447 is only directed to the fact that nitric oxide is eluted from the coating during a period of time, i.e. that the nitric oxide not is eluted all in once. Therefore, the interpretation of "controlled" in respect of US 6,737,447 is different from the meaning of "regulating" in the present invention. "Regulate or control", according to the present invention is intended to be interpreted as the possibility to vary the elution of nitric oxide to thereby achieve different elution profiles.

A polymer comprising an O-nitrosylated group is also a possible nitric oxide eluting polymer. Thus, in one embodiment of the present invention, the nitric oxide eluting polymer comprises diazoniumdiolate groups, S-nitrosylated and O-nitrosylated groups, or any combinations thereof.

In still another embodiment of the present invention said nitric oxide eluting polymer is a poly(alkyleneimine)diazoniumdiolate, such as L-PEI-NO (linear poly(ethyleneimine)diazoniumdiolate), where said nitric oxide eluting polymer is loaded with nitric oxide through the diazoniumdiolate groups and arranged to release nitric oxide at a treatment site.

Some other examples of a suitable nitric oxide eluting polymer are selected from the group comprising amino cellulose, amino dextrans, chitosan, aminated chitosan, polyethyleneimine, PEI-cellulose, polypropyleneimine, polybutyleneimine, polyurethane, poly(buthanediol spermate), poly(iminocarbonate), polypeptide, Carboxy Methyl Cellulose (CMC), polystyrene, poly(vinyl chloride), and polydimethylsiloxane, or any combinations of these, and these mentioned polymers grafted to an inert backbone, such as a polysaccharide backbone or cellulosic backbone.

In still another embodiment of the present invention the nitric oxide eluting polymer may be a O-derivatized NONOate. This kind of polymer often needs an enzymatic reaction to release nitric oxide.

Other ways of describing polymers, which may be suitable as nitric oxide eluting polymer, is polymers comprising secondary amine groups ($=N-H$), such as L-PEI, or have a secondary amine ($=N-H$) as a pendant, such as aminocellulose.

It is preferable that the nano-spun fibres in the NO-eluting sponge according to the embodiment of present invention comprise L-PEI. This embodiment of course permits the sponge to be placed in another location in the oral cavity than between the lip and the teeth. When placed on an area to be treated the device provides for promotion of osteosynthetic and soft tissue healing, as well as prevention and treatment of paradontosis, infections or wounds, thanks to the effect of NO eluting from the sponge into the regions to be treated. One of the advantages of electrospun or gas-jet spun nanofibres is their large surface area per volume unit. For the sponge this leads to a very effective treatment with a compact device.

One field of application of the device is post dental implant, e.g. accelerated healing thereof, or post-

operative infection control, which is simplified and made more effective and convenient by the invention.

Other example for NO eluting polymers are given in US-5,770,645, wherein polymers derivatized with at least one -NOX group per 1200 atomic mass unit of the polymer are disclosed, X being one or two. One example is an S-nitrosylated polymer and is prepared by reacting a polythiolated polymer with a nitrosylating agent under conditions suitable for nitrosylating free thiol groups. Such polymers may also be used for other embodiments of the devices according to the present invention. However, L-PEI is preferred, as the NO is eluted without any secondary products that could lead to undesired side effects as a result of treatment with the devices described herein.

In another embodiment the device according to present invention is in the form of a pad or patch 20, according to Fig. 2. The pad or patch is coated with or comprises at least partly, at least on one side, nano-spun fibres, which according to embodiments of the present invention comprise the materials mentioned above, regarding the sponge. The nano-spun fibres elute NO in a therapeutic dose as the nano-spun fibres that release NO, which is eluted from the fibres without harmful secondary or waste products, are activated for this purpose when they get in contact with the moisture in the oral cavity. This embodiment has the advantage that it is easily applicable, and removable, on, and from, the target area. Furthermore, this pad or patch has the advantage that it is easily activated. Furthermore, the NO is applied locally, without influencing other parts of the body, due to the short half-life of the NO eluted from the NO eluting polymer material. Alternatively, if the oral cavity of some reason should be deprived of humidity, the patch, and also other devices according to embodiments of the invention, may be activated immediately prior to

introduction or in the cavity, e.g. by moisturizing them in a bath of water or by a water sprayed onto the device.

The device according to this embodiment of the present invention may in a further embodiment be soluble in the oral cavity. When the device is subjected to the moisture in the oral cavity, the device is disintegrated in its entirety, wherein the time for dissolving the device is adapted to specific requirements, as for instance therapeutic concentrations to be released over time. This embodiment has the advantage that it is easily applicable and does not have to be removed for replacement by another device or after the therapeutic treatment with the device is completed.

In another embodiment of the present invention the device or system only allows NO-elution in one direction. In this kind of embodiment one side of the device according to the invention has low permeability, or substantially no permeability, to nitric oxide. This may be accomplished by applying a material on one side of the device according to the invention that is not permeable to NO. Such materials may be chosen from the group comprising common plastics, such as fluoropolymers, polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these. This embodiment is also easy to manufacture as the NO eluting polymer, e.g. L-PEI (or nitric oxide eluting polymer and carrier material, which will be explained in more detail below) may be electro or gas-jet spun onto the surface of the device according to the invention of e.g. the mentioned plastics, latex, or cotton.

In still another embodiment the device is provided with one membrane, which is permeable to nitric oxide, on a first side of the device, and another membrane, which has low permeability or substantially no permeability to nitric oxide, on a second side of said device. This embodiment provides the possibility to direct the elution to said first of the device, while the elution of nitric oxide is substantially prevented from said second side. Thereby, a greater amount of nitric oxide will reach the intended area to be treated.

In another embodiment of the present invention the device only allows NO-elution in one direction, according to Fig. 3. In this kind of embodiment one side of the patch or pad 30 is non-permeable to NO. This may be accomplished by applying a material on one side of the patch or pad that is not permeable to NO. Such materials may be chosen from the group comprising common plastics, such as polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these. In this way, the therapeutic effect of NO is easily directable to certain regions in the oral cavity without interfering with other regions therein.

A further embodiment of the invention is illustrated in Fig. 4, in which the device is shaped as a condom/sheath 40, which either is made of an NO eluting polymer or coated with it, e.g. by nano electro-spinning or gas-jet spinning. According to this embodiment the condom/sheath may be mounted on a stick 41 for easier application. The condom/sheath may be applied by inserting the stick, with the condom/sheath according to the present invention

mounted thereon, adjacent to the area to be treated. Then the stick may be extracted from the oral cavity. The condom/sheath is left adjacent to the area to be treated. This area may be areas such as in between the teeth, the tooth pocket, or any other area in the oral cavity where the condom/sheath is applicable.

This condom/sheath may of course be in any suitable size, such as a size suitable for inserting said condom/sheath between the teeth or in a tooth pocket. The condom/sheath is then inserted on the preferred area to be treated with the aid of a suitable means, such as a stick or pin. This embodiment has the advantages that it is easy to pin point the treatment area and it is easy to apply.

In still another embodiment of the present invention NO-eluting nano-particles, or micro-spheres, may be formed from NO-eluting polymers, according to Fig. 5. These nano-particles, e.g. in the form of micro-spheres may be integrated in a soluble film that disintegrates e.g. in between the lip and the dental soft tissue, in the dental pocket, or any other area in the oral cavity where the device is applicable, in order to elute NO at the area of interest when soluble film gets in contact with the moisture in the oral cavity, or between the inside of the cheek and the gum, in one direction or both.

In another embodiment of the present invention the nano-particles, or micro-spheres, of the polymers in the present invention, may be encapsulated in a material that breaks upon the stress from chewing or brushing the teeth. Then said nano-particles, or micro-spheres, may be integrated in chewing gum or toothpaste. This kind of chewing gum or toothpaste may then be used to prevent or treat disorders in the oral cavity, such as infections, cancer, or paradontosis, or to promote osteosynthesis and soft tissue healing post dental implant. The materials used to encapsulate these nano-particles, or micro-spheres, may

be chosen from the group comprising polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, 5 polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these. This embodiment has the advantages 10 that it is easy to apply, the treatment effect covers the whole oral cavity, and it is easy to manufacture.

In the context of the present invention the term "encapsulating" is intended to be interpreted as fixating the nitric oxide eluting polymer in a three dimensional 15 matrix such as a foam, a film, a nonwoven mat of nano-fibers or fibers, other materials with the capability to fixate the NO eluting polymer, or enclosing the nitric oxide eluting polymer in any suitable material.

In still another embodiment of the present invention 20 the nano-particles, or micro-spheres, may combined with a suitable mouthwash, such as chlorine dioxide (ClO_2), according to Fig. 6. When the mouthwash is used in the oral cavity, the nano-particles, or micro-spheres, break and NO is released. Of course, chlorine dioxide may be combined 25 with all the embodiments according to the present invention, such as the patch. This offers the advantage of further promoting the anti-bacterial effect of NO.

In yet another embodiment of the present invention the NO-eluting device is acting as a booster for drug 30 eluting patches, e.g. pharmaceuticals, vitamins, nicotin, nitroglycerin etc. This embodiment presents a device with the advantage of combining two therapeutic treatments, of significant value, in one treatment. A synergetic effect may be that NO that is eluted from the device has a 35 vasodilatory effect on the region where the device having

the combination compound actuates. Vasodilated tissue is more is more susceptible to certain medications and thus more easily treated by the medical preparations and still NO has in addition to that the anti-inflammatory, anti-
5 bacterial etc. effect. Hence, an unexpected surprisingly effective treatment is provided.

In still another embodiment the nitric oxide eluting polymer, such as powder, nano-particles or micro-spheres, can be incorporated in foam. The foam may have an open cell
10 structure, which facilitates the transport of the proton donor to the nitric oxide eluting polymer. The foam can be of any suitable polymer such as polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose,
15 polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any
20 combinations of these.

In another embodiment the device is in form of a cream, a gel or a combination of the two. This embodiment has the advantage of being able to penetrate pockets and corners, e.g in the gum or skin for closer elution of NO on
25 the area to be treated.

In another embodiment the device is in form of a cream, a gel or a combination of the two. Since the nitric oxide eluting polymer is activated by proton donors the nitric oxide eluting polymer has to be separate from the
30 proton donor until one wants to initiate the elution of nitric oxide, i.e. use the device. One way to accomplish this is to have a syringe with two separate containers. In one container you have a proton donor-based gel and in the other a non proton donor-based gel, comprising the nitric
35 oxide eluting polymer. Upon using the device the two gels

are squeezed from the syringe and mixed together, the proton donor in the first gel comes in contact with the nitric oxide eluting polymer in the second gel and the elution of nitric oxide starts.

5 In still another embodiment of the present invention dental implants, such as screws of titanium, and other biodegradable or biocompatible plates, may be integrated with the fibres, nano-particles, or micro-spheres according to the present invention, e.g. by coating the devices. A
10 very convenient way for coating is offered by electro-spinning or gas-jet spinning of NO eluting polymers onto the surface of the devices. This embodiment decreases the risk of infections during surgical procedures in the oral cavity.

15 The device may include materials such as polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene,
20 polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these. The NO-eluting polymer may be integrated in, spun together with, or spun
25 on top of, any of these materials in all of the embodiments of the present invention.

 Three important factors in controlling and regulating the elution of nitric oxide from a nitric oxide eluting polymer are how quickly a proton donor comes in contact
30 with the nitric oxide releasing polymer, such as a diazolumdiolate group, the acidity of the environment surrounding the nitric oxide eluting polymer, and the temperature of the environment surrounding the nitric oxide releasing polymer (higher temperature promotes elution of
35 nitric oxide).

In one embodiment of the present invention a nitric oxide eluting polymer, such as L-PEI-NO, is mixed with a carrier polymer to slow down or prolong the elution of nitric oxide. Also, in another embodiment, the nitric oxide eluting polymer may be mixed with more than one carrier polymer, whereby the elution or release may be tailor made to fit specific needs. Such a need may for example be a low elution during a first period of time, when the environment of the nitric oxide eluting polymer is hydrophobic, and a faster elution during a second period of time, when the environment of the nitric oxide eluting polymer has been altered to be more hydrophilic. This may for example be accomplished by using biodegradable polymers, whereby a low elution during a first period of time is obtained, after which, when the hydrophobic polymer has been dissolved, the hydrophilic polymer provides a higher elution of nitric oxide. Thus, a more hydrophobic carrier polymer will give a slower elution of nitric oxide, since the activating proton donor, such as water or body fluid, will penetrate the carrier polymer slower. On the other hand, a hydrophilic polymer acts the opposite way. One example of an hydrophilic polymer is polyethylene oxide, and one example of an hydrophobic polymer is polystyrene. These carrier polymers may be mixed with the nitric oxide eluting polymer and then electrospun to suitable fibers. The skilled person in the art knows which other polymers may be used for similar purposes. Fig. 7 illustrates two elution profiles (NO concentration vs. time) for two different polymer mixtures; a nitric oxide eluting polymer mixed with a hydrophilic carrier polymer in an acidic environment (A), and a nitric oxide eluting polymer mixed with a hydrophobic carrier polymer in a neutral environment (B).

In one embodiment this carrier polymer is substituted by another material with hydrophobic or hydrophilic properties. Therefore, the term "carrier material" in the

present context should be interpreted to include carrier polymers and other materials with hydrophilic or hydrophobic properties.

In another embodiment of the present invention the elution of nitric oxide from a nitric oxide eluting polymer, such as L-PEI-NO, is influenced by the presence of protons. This means that a more acidic environment provides a quicker elution of nitric oxide. By activating the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material, with an acidic fluid, such as an ascorbic acid solution, the elution of nitric oxide may be accelerated.

The carrier polymers and carrier materials mentioned in above may affect other characteristics than the regulation of nitric oxide elution. An example of such characteristic is mechanical strength.

In respect of the carrier polymers or carrier materials, the NO-eluting polymer may be integrated in, spun together with, or spun on top of, any of these materials in all of the embodiments of the present invention. This spinning includes electrospinning, air spinning, wet spinning, dry spinning, melt spinning, gel spinning. In this way, one may manufacture fibers of a polymer mixture, comprising a nitric oxide eluting polymer and a carrier polymer, or a carrier material, with predefined nitric oxide eluting characteristics. These characteristics may be tailor made for different elution profiles in different applications.

The device elutes nitric oxide (NO) from said eluting polymer in a therapeutic dose, such as between 0.001 to 5000 ppm, such as 0.01 to 3000 ppm, such as 0.1 to 1000 ppm, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59,

60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 ppm. The concentration may vary widely depending on where the
5 concentration is measured. If the concentration is measured close to the actual NO eluting polymer the concentration may be as high as thousands of ppm, while the concentration inside the tissue in this case often is considerably lower, such as between 1 to 1000 ppm.

10 In the embodiments of the present invention it may be suitable to control or regulate the time span of NO release from the device according to the invention. This may be accomplished by integrating other polymers or materials in said device. These polymers or materials may be chosen from
15 any suitable material or polymer, such as polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates,
20 polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these.

The sizes of the devices according to the present
25 invention may of course vary widely within in the parameters conveniently used in the oral cavity, but the size is typically 7 to 15 mm X 20 to 40 mm, preferably 9 to 13 mm X 25 to 35 mm, such as 10 mm X 30 mm.

The NO-eluting polymers in the devices according to
30 the present invention may be combined with silver, such as hydroactivated silver. The integration of silver in the devices according to the present invention gives the healing process an extra boost. Preferably the silver is releasable from the devices in the form of silver ions. The
35 integration of silver in the device may present several

advantages. One example of such an advantage is that the silver may keep the device in itself free from bacteria or viruses, while the nitric oxide eluting polymer elutes the therapeutic dosage of nitric oxide to the target site.

5 The nitric oxide eluting polymer may comprise a secondary amine, either in the backbone or as a pendant, as described previously. This will make a good nitric oxide eluting polymer. The secondary amine should have a strong negative charge to be easy to load with nitric oxide. If
10 there is a ligand close to the secondary amine, such as on a neighbour atom, such as a carbon atom, to the nitrogen atom, with higher electronegativity than nitrogen (N), it is very difficult to load the polymer with nitric oxide. On the other hand, if there is a electropositive ligand close
15 to the secondary amine, such as on a neighbour atom, such as a carbon atom, to the nitrogen atom, the electronegativity of the amine will increase and thereby increase the possibility to load the nitric oxide elution polymer with nitric oxide.

20 In an embodiment of the present invention the nitric oxide polymer may be stabilized with a salt. Since the nitric oxide eluting group, such as a diazeniumdiolate group, usually is negative, a positive counter ion, such as a cation, may be used to stabilize the nitric oxide eluting
25 group. This cation may for example be selected from the group comprising any cation from group 1 or group 2 in the periodic table, such as Na^+ , K^+ , Li^+ , Be^{2+} , Ca^{2+} , Mg^{2+} , Ba^{2+} , and/or Sr^{2+} . Different salts of the same nitric oxide eluting polymer have different properties. In this way a
30 suitable salt (or cation) may be selected for different purposes. Examples of cationic stabilized polymers are L-PEI-NO-Na, i.e. L-PEI diazeniumdiolate stabilized with sodium, and L-PEI-NO-Ca, i.e. L-PEI diazeniumdiolate stabilized with calcium.

Another embodiment of the present invention comprises mixing the nitric oxide eluting polymer, or a mixture of the nitric oxide eluting polymer and a carrier material, with an absorbent agent. This embodiment provides the advantage of an accelerated elution of nitric oxide since the polymer, or polymer mixture, via the absorbent agent, may take up the activating fluid, such as water or body fluid, much faster. In one example 80 % (w/w) absorbent agent is mixed with the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material, and in another embodiment 10 to 50 % (w/w) absorbent agent is mixed with the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material.

Since the elution of nitric oxide is activated by a proton donor, such as the water in the oral cavity, it may be an advantage to keep the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material, in contact with said proton donor. If an indication requires an elution of nitric oxide during a prolonged period of time, a system is advantageous, which presents the possibility to keep the proton donor in contact with the nitric oxide eluting polymer, or mixture of nitric oxide eluting polymer and carrier material. Therefore, in still another embodiment of the present invention, the elution of nitric oxide may be regulated by adding an absorbent agent. The absorbent agent absorbs the proton donor, such as water, and keeps the proton donor in close contact with the nitric oxide eluting polymer during prolonged periods of time. Said absorbent agent may be selected from the group comprising polyacrylates, polyethylene oxide, carboxymethylcellulose, and microcrystalline cellulose, cotton, and starch. This absorbent agent may also be used as a filling agent. In this case said filling agent may give the nitric oxide

eluting polymer, or mixture of said nitric oxide eluting polymer and a carrier material, a desired texture.

The device may be manufactured by, for example electro spinning of L-PEI. L-PEI is the charged at a
5 characteristic voltage, and a fine jet of L-PEI releases as a bundle of L-PEI polymer fibres. This jet of polymer fibres may be directed to a surface to be treated. The surface to be treated may for example be any suitable material in respect of a device. The electro spun fibres of
10 L-PEI then attach on said material and form a coating/layer of L-PEI on the device according to the invention.

It is of course possible to electro spin the other NO-eluting polymers, according to above, on the device according to the invention while still being inside the
15 scope of the present invention.

Other manufacturing methods, such as wet spinning, dry spinning, melt spinning, and gel spinning, are also within the scope of the present invention.

In one embodiment the NO-eluting polymers according
20 to the present invention are elctro spun in such way that pure NO-eluting polymer fibres may be obtained.

Gas stream spinning, air spinning, wet spinning, dry spinning, melt spinning, and gel spinning, of said NO-eluting polymers onto the device is also within the scope
25 of the present invention.

The manufacturing process according to the present invention presents the advantages of large contact surface of the NO-eluting polymer fibres with the area to be treated, effective use of NO-eluting polymer, and a cost
30 effective way of producing the device.

The device according to the invention may of course be used in any post surgery treatment to prevent, treat, and/or alleviate any kind of infection or inflammation. Especially to prevent disorders post surgery in the oral
35 cavity. The effects of NO are provided in a convenient way

by the device of the invention. Such effects are for instance, as mentioned above, anti-inflammatory, anti-pathogenic, especially anti-viral and anti-bacterial. Furthermore the anti-cancerous effect of NO may be taken
5 advantage of, e.g. for bone cancer treatment of the jaw.

Hereinafter some potential uses of the present invention are described:

A method of therapeutically treating disorders in the oral cavity, comprising introducing a stick or pin having
10 releasably attached thereto a device according any of claims 1-6 into the oral cavity of a patient, releasing the device, in the oral cavity of the patient, from the stick or pin, thereby contacting an area of treatment in the oral cavity, such that a therapeutic dose of nitric oxide is
15 eluted from said nitric oxide eluting polymer to said area.

The method according to the above, wherein said area of treatment is an infected area in the oral cavity or an area where infection is to be prevented for treatment by the effect of the device.

20 The method according to the above, wherein said treatment area is a post-operative dental surgery area.

The method according to the above, wherein said treatment area is a tumor area in the oral cavity.

Use of nitric oxide (NO) in a therapeutic dose for
25 the treatment of disorders in the oral cavity, wherein said use for instance is the treatment or prevention of parodontosis.

The invention can be implemented in any suitable form. The elements and components of the embodiments
30 according to the invention may be physically, functionally, and logically implemented in any suitable way. Indeed, the functionality may be implemented in a single unit, in a plurality of units, or as part of other functional units.

Although the present invention has been described
35 above with reference to specific embodiments, it is not

intended to be limited to the specific form set forth herein. Rather, the invention is limited only by the accompanying claims and, other embodiments than the specific above are equally possible within the scope of
5 these appended claims.

In the claims, the term "comprises/comprising" does not exclude the presence of other elements or steps. Furthermore, although individually listed, a plurality of means, elements or method steps may be implemented.
10 Additionally, although individual features may be included in different claims, these may possibly advantageously be combined, and the inclusion in different claims does not imply that a combination of features is not feasible and/or advantageous. In addition, singular references do not
15 exclude a plurality. The terms "a", "an", "first", "second" etc do not preclude a plurality. Reference signs in the claims are provided merely as a clarifying example and shall not be construed as limiting the scope of the claims in any way.

20

CLAIMS

1. A device configured to therapeutically treat and/or prevent disorders in the oral cavity, wherein
5 said device comprises a nitric oxide (NO) eluting polymer configured to elute a therapeutic dosage of nitric oxide (NO) when used for said treatment and/or prevention of a target site in the oral cavity, and wherein said device is configured to expose said target site to said
10 nitric oxide when said polymer in use elutes nitric oxide (NO),
c h a r a c t e r i z e d in that
said nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material,
15 in use, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO).
2. Device according to claim 1, wherein said nitric oxide (NO) eluting polymer comprises diazeniumdiolate
20 groups, S-nitrosylated groups, and O-nitrosylated groups, or any combination of these.
3. Device according to claim 1 or 2, wherein said nitric oxide (NO) eluting polymer is L-PEI (linear
25 polyethyleneimine), loaded with nitric oxide (NO) through said diazeniumdiolate groups, S-nitrosylated groups, or O-nitrosylated groups, or any combination these, arranged for release of the nitric oxide (NO) at said target site in the oral cavity.
30
4. Device according to claim 1, wherein said nitric oxide eluting polymer is selected from the group comprising amino cellulose, amino dextrans, chitosan, aminated
chitosan, polyethyleneimine, PEI-cellulose,
35 polypropyleneimine, polybutyleneimine, polyurethane, poly(buthanediol spermate), poly(iminocarbonate),

polypeptide, Carboxy Methyl Cellulose (CMC), polystyrene, poly(vinyl chloride), and polydimethylsiloxane, or any combinations of these, and these mentioned polymers grafted to an inert backbone, such as a polysaccharide backbone or
5 cellulosic backbone.

5. Device according to claim 1, in form of a sponge, a pad or patch, a condom/sheath, adapted to be applied in the oral cavity.

10

6. Device according to any of claims 1, 2, 3, 4, or 5, wherein said device is configured to be applied to the oral cavity by the aid of a stick or pin.

15

7. Device according to claim 1, wherein said device is configured to disintegrate in the oral cavity when subjected to moisture or water.

8. Device according to claim 1, wherein said NO-eluting polymer is combined with silver, configured to therapeutically treat said area of treatment in the oral cavity.

20

9. Device according to claim 1, wherein said carrier material, regulating or controlling NO-elution, is selected from the group comprising polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any combinations of these.

25

30

10. Device according to claims 1 to 9, comprising said nitric oxide eluting polymer in the form of nano-particles or micro-spheres.

5 11. Device according to claim 10, wherein said nano-particles, or micro-spheres, are encapsulated in a material selected from the group comprising polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose,
10 polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable polymers, cotton, and latex, or any
15 combinations of these.

12. Device according to claim 10 or 11, wherein said nano-particles or micro-spheres are integrated in a toothpaste.

20

13. Device according to claim 10 or 11, wherein said nano-particles or micro-spheres are integrated in a chewing gum.

25 14. Device according to claim 10 or 11, wherein said nano-particles or micro-spheres are integrated in a mouth wash.

15. Device according to claim 14, wherein said mouth
30 wash comprises chlorine dioxide.

16. Device according to claim 1, wherein said nitric oxide eluting polymer comprises a secondary amine in the backbone or a secondary amine as a pendant.

35

17. Device according to claim 16, wherein a positive ligand is located on a neighbour atom to the secondary amine.

5 18. Device according to claim 1 or 9, comprising an absorbent agent.

19. Device according to claim 18, wherein said absorbent agent is selected from the group comprising
10 polyacrylate, polyethylene oxide, Carboxy Methyl Cellulose (CMC), microcrystalline cellulose, cotton, or starch, or any combinations thereof.

20. Device according to claim 1, 9, 16, 17, or 18,
15 comprising a cation, said cation stabilizing the nitric oxide eluting polymer.

21. Device according to claim 20, wherein said cation is selected from the group comprising Na^+ , K^+ , Li^+ , Be^{2+} ,
20 Ca^{2+} , Mg^{2+} , Ba^{2+} , and/or Sr^{2+} , or any combinations thereof.

22. Device according to claim 1, comprising a first membrane, which is permeable to nitric oxide, on a first side of the device, in use directed to said first side,
25 preferably in use oriented towards said treatment site, and a second membrane, which has low permeability or substantially no permeability to nitric oxide, on a second side of said device, preferably oriented away from said treatment site, such that elution of nitric oxide in use is
30 directed towards said first side, while the elution of nitric oxide in use is substantially prevented from said second side.

23. Device according to claim 1, wherein the nitric oxide eluting polymer is a powder, nano-particles or micro-
35 spheres, and incorporated in a foam.

24. Device according to claim 23, wherein the foam has an open cell structure configured to facilitate transport of a proton donor to the nitric oxide eluting
5 polymer.

25. Device according to claim 24, wherein the foam comprises a polymer, such as polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates,
10 polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatine, biodegradable
15 polymers, cotton, and latex, or any combinations of these.

26. Device according to claim 1, wherein the device is a syringe-type device having two separate containers, wherein a first container contains a proton donor-based NO
20 release activation agent, such as a gel, and a second container contains a non proton donor-based gel, comprising the nitric oxide eluting polymer, wherein the syringe-type device is configured to provide admixing upon administration to a cosmetic treatment site.

25

27. A manufacturing process for a device configured to therapeutically treat and/or prevent disorders in the oral cavity according to claim 1, comprising:
30 selecting a nitric oxide (NO) eluting polymer configured to elute a therapeutic dosage of nitric oxide (NO) in the oral cavity when used for said therapeutic treatment and/or prevention,

selecting a carrier material, which carrier material is configured to regulate and control the elution of said therapeutic dosage of nitric oxide (NO),

5 incorporating the NO-eluting polymer with said carrier material into an nitric oxide (NO) eluting material, such that said carrier material, in use of said device, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO), and

10 deploying said nitric oxide eluting material into a suitable form, or as a coating onto a carrier, to form at least a part of said device, such that said device is configured to expose a therapeutic target site in the oral cavity to said nitric oxide when said NO-eluting polymer in use elutes nitric oxide (NO).

15

28. The manufacturing process according to claim 27, wherein said deploying comprises electro spinning, air spinning, gas spinning, wet spinning, dry spinning, melt spinning, or gel spinning of NO-eluting polymer.

20

29. The manufacturing process according to claim 27 or 28, wherein said selecting said nitric oxide (NO) eluting polymer comprises selecting a plurality of nitric oxide (NO) eluting polymeric particles, preferably nano fibres, nano particles or micro spheres.

25

30. The manufacturing process according to claim 27 or 28, wherein said incorporating said NO-eluting polymer with said carrier material comprises integrating said NO-eluting polymer in said carrier material, spinning said NO-eluting polymer together with said carrier material, or spinning said NO-eluting polymer on top of said carrier material, in order to predefine nitric oxide eluting characteristics of said device.

35

31. The manufacturing process according to claim 27, further comprising integrating silver in said device.

32. Use of a nitric oxide (NO) eluting polymer and a
5 carrier material for the manufacture of a device for the treatment of disorders in the oral cavity,
wherein nitric oxide is loaded to said device so that the device elutes nitric oxide (NO) from said eluting polymer in a therapeutic dose when used in the oral cavity,
10 and said carrier material regulates and/or controls the elution of nitric oxide.

33. Use according to claim 32, wherein said
therapeutic dose is 0.001 to 5000 ppm, such as 0.01 to 3000
15 ppm, such as 0.1 to 1000 ppm, such as 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,
38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,
53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,
20 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90 91, 92, 93, 94, 95, 96, 97,
98, 99, or 100 ppm..

34. A method of therapeutically treating disorders in
25 the oral cavity, comprising introducing a stick or pin having releasably attached thereto a device according any of claims 1 to 8 into the oral cavity of a patient, releasing the device, in the oral cavity of the patient, from the stick or pin, thereby contacting an area of
30 treatment in the oral cavity, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area.

35. The method according to claim 34, wherein said
35 area of treatment is an infected area in the oral cavity or

an area where infection is to be prevented for treatment by the effect of the device.

36. The method according to claim 35, wherein said
5 treatment area is a post-operative dental surgery area.

37. The method according to claim 34, wherein said treatment area is a tumor area in the oral cavity.

10 38. Use of nitric oxide (NO) in a therapeutic dose for the treatment of disorders in the oral cavity.

39. Use of Nitric Oxide (NO) according to claim 38,
wherein said treatment is a therapeutic treatment of
15 paradontosis in the oral cavity.

1/4




Fig. 1




Fig. 7

2/4




Fig. 2

20




Fig. 3

30

3/4




Fig. 4

4/4




Fig. 5




Fig.6

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/050888

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61L27/54 A61L29/16 A61L31/16 A61L27/34 A61L29/08
 A61L31/10 A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61L A61K C09D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/094985 A1 (HERRMANN ROBERT A ET AL) 18 July 2002 (2002-07-18) paragraph [0026] paragraph [0036] paragraph [0037] paragraph [0040] - paragraph [0043] paragraph [0059] - paragraph [0100] -----	1-4, 9, 20, 27, 30
X	WO 03/086282 A (NITROMED, INC; FANG, XINQIN; GARVEY, DAVID, S; GASTON, RICKY, D; LIN,) 23 October 2003 (2003-10-23) page 1, line 5 - line 25 page 3, line 16 - line 32 page 34, line 18 - page 36, line 25 page 49, line 26 - page 50, line 9 page 52, line 3 - line 12 ----- -/--	1, 2, 5, 6, 9-11, 16, 18, 19, 27



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

31 May 2006

Date of mailing of the international search report

12/06/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Staber, B

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/050888

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 110 453 A (KEEFER ET AL) 29 August 2000 (2000-08-29) column 3, line 22 - line 37 column 5, line 19 - line 24 column 8, line 50 - line 58 -----	1-7, 10
X	US 2004/265244 A1 (ROSEN GERALD M) 30 December 2004 (2004-12-30) paragraph [0008] paragraph [0027] -----	1, 5-7, 9, 27, 30, 32, 38
X	EP 1 300 424 A (MEDTRONIC AVE INC) 9 April 2003 (2003-04-09) paragraph [0001] paragraph [0023] paragraph [0032] -----	1-3, 5, 6, 9, 10
X	US 5 958 427 A (SALZMAN ET AL) 28 September 1999 (1999-09-28) column 6, line 18 - line 19 column 10, line 31 - line 35 column 11, line 47 - line 57 column 12, line 26 - line 32 -----	1-4, 32, 38
X	US 5 691 423 A (SMITH ET AL) 25 November 1997 (1997-11-25) column 4, line 12 - line 21 column 8, line 26 - line 33 -----	1, 5, 10
X	GB 2 354 441 A (* MCCORMACK LIMITED) 28 March 2001 (2001-03-28) page 2, line 19 - line 27 page 5, line 19 - line 25 -----	38

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/050888

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002094985 A1	18-07-2002	CA 2443895 A1 EP 1399134 A2 JP 2005503834 T WO 02056864 A2 US 2004171589 A1	25-07-2002 24-03-2004 10-02-2005 25-07-2002 02-09-2004
WO 03086282 A	23-10-2003	AU 2003223491 A1 CA 2480832 A1 EP 1497268 A2 JP 2005537223 T	27-10-2003 23-10-2003 19-01-2005 08-12-2005
US 6110453 A	29-08-2000	NONE	
US 2004265244 A1	30-12-2004	NONE	
EP 1300424 A	09-04-2003	JP 2003201313 A US 2005079148 A1 US 2003077243 A1	18-07-2003 14-04-2005 24-04-2003
US 5958427 A	28-09-1999	AU 5167398 A CA 2271013 A1 EP 0937035 A1 JP 2002511838 T WO 9819996 A1 ZA 9710015 A	29-05-1998 14-05-1998 25-08-1999 16-04-2002 14-05-1998 25-05-1998
US 5691423 A	25-11-1997	US 5525357 A US 5718892 A US 5676963 A US 5405919 A	11-06-1996 17-02-1998 14-10-1997 11-04-1995
GB 2354441 A	28-03-2001	NONE	